Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426559 | 0.88 | L3MBTL1 (0.66) | NPC1L3MBTL1HPGDALDH1A1MAPT | |
| SCHEMBL7163067 | 0.87 | L3MBTL1 (0.73) | NPC1L3MBTL1HPGDCYP3A4ALDH1A1 | |
| SCHEMBL14426553 | 0.84 | HPGD (0.78) | NPC1L3MBTL1HPGDPOLBALDH1A1 | |
| SCHEMBL14426539 | 0.82 | CYP3A4 (0.75) | NPC1HPGDPOLBCYP3A4ALDH1A1 | |
| SCHEMBL7081917 | 0.82 | NPC1 (0.61) | NPC1HPGDPOLBCYP3A4ALDH1A1 | |
| SCHEMBL7929903 | 0.81 | NPC1 (0.59) | NPC1L3MBTL1HPGDPOLBCYP3A4 | |
| SCHEMBL11667316 | 0.81 | NPC1 (0.59) | NPC1HPGDPOLBCYP3A4ALDH1A1 | |
| SCHEMBL2091861 | 0.80 | NPC1 (0.55) | NPC1HPGDRAB9A | |
| SCHEMBL13964428 | 0.80 | NPC1 (0.72) | NPC1HPGDPOLBCYP3A4ALDH1A1 | |
| SCHEMBL14422909 | 0.80 | KDR (0.64) | L3MBTL1HPGDPOLBCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | SANOFI-AVENTIS (FR) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203184-A1 | Novel Indolin-2-one Derivatives, Their Preparation and the Pharmaceutical Compositions Comprising Them | OXTR, AVPR2, AVPR1B | NPC1 2582/4885L3MBTL1 4873/4885HPGD 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.